I owe THCB readers a follow-up piece on King-Drew Medical Center and have had it in the queue since Christmas, but I’m crunched with other work and the blog pieces are suffering as a consequence. So meanwhile please go read this excellent piece from the New Republic’s Jonathan Cohn on charity care and whether hospitals are delivering enough: Uncharitable?

Given that at one point in my life I was a futurist and that I still claim to know something about forecasting, let me start 2005 at THCB by telling you what I think may be the big trends to look out for this year. I’m not going to necessarily tell you what the end results will be, but if you are interested in health care, and working on topics that matter to you and your organizations, these issues are where you may both see plenty of activity and also spend much of your time.

So in no particular order

FDA reform: Last years revelations included unsuccessful clinical trials going unreported, data being selectively reported in major journals, information not released to the public when it was available to the FDA, and drugs being put on (and in at least the case of Vioxx taken off) the market without full disclosure of the dangers that were known to the manufacturers. Furthermore the blame for all this is shared between pharma, the FDA and the main medical journals. There may be good reasons for keeping potentially dangerous drugs available for physicians to prescribe (see Sydney’s sensible view in the last paragraph of this post at Medpundit). But I urge you to read John Abramson’s Overdosed America which demonstrates how poorly the information that’s known about the use of drugs and other therapies is presented to the public and the medical profession. Even with the domination of all branches of government by the Republicans, it’s unlikely that nothing significant will be done to the FDA. Look for the bolstering of the post-market surveillance function, and also for an enhancement of the clinical trials.gov site as better reporting of all trials is demanded by governments internationally. However, we’re not ready for an American NICE just yet.

Medicare “Modernization” (or NAIM as Jeanne Scott calls it or TEOMAWKI as I called it after Ross wrote about it–prizes for those figuring out the acronyms). There is going to be a great deal of mind-numbing details to be sorted out in 2005 regarding how much of what’s happening in Medicare this year and next will work. Five quick ones are:

• How the Part D private drug benefit plans are going to be developed, marketed and chosen, and what they’re going to have to include in their formularies, and how much lee-way they’ll have to negotiate with pharma
• How (and if) the new Medicare Advantage PPOs are going to work cross-state-borders.
• Will the Medicare Advantage HMOs grow as fast as Wall Street thinks they will with the new money going to the plans?
• What will be the real progress of the Medicare CCIP disease management programs? This will be the focus of disease management wonks for the next 24 months.
• Everyone involved in the business of injectable drugs for oncology, ESRD, etc paid for by Medicare Part B will continue to scramble to figure out what’s really going to happen and what “ASP plus 6%” really means.

My impression is that the next 2-3 years will see slightly slower transformation of Medicare than the hype would have us believe. Most seniors will stick with their current drug coverage, and employers will be relatively reluctant to dump their retirees from Medigap coverage immediately. Most seniors will be somewhat reticent to go back into the HMOs which dumped them a few years back. And eventually the Congress will notice that paying private plans more for something the main Medicare program can deliver cheaper is not great business in a time of ever largening deficits. So I’m not among those thinking that the traditional Medicare program will be gone in a few years. But for those of you in the business there is a lot of work to be done figuring out the details of these new programs.

Pharma Marketing Reform: I don’t think that the FDA will ban DTC advertising quite yet, and I don’t think that the current Congress will get too involved in regulation of pharma marketing. But I do think that the slow changes seen last year in the way that big pharma itself does its sales and marketing will become more obvious. Results are starting to come in that some of this electronic detailing and other approaches to marketing are more cost-effective than sending out reps. Sales teams are the biggest empires in big pharma, and big empires only change in times of stress. But stress in the form of some big patent expiries and some unexpected pulls of drugs from the market–and the associated decrease in revenue–is on the way (or already here in Merck’s case). Despite all the money spent on data and sales force automation, there is room for a lot more efficiency in this area. Expect pharma to grapple with making their sales forces smaller, more effective at physician targeting, and less willing to use the technique of throwing vast quantities of mud at the wall and hoping that some of it sticks.

Medical Errors: Michael Millenson will continue to write articles about how appallingly slow the response by the health care system and medical profession has been in responding to the crisis. The current slow rate of CPOE installation will pick up the pace oh-so-slightly, and going to the hospital in the US (and the UK) will remain a somewhat dangerous endeavor. Congress will do, effectively, nothing. (Yes that’s an actual real-life prediction).

Malpractice: Medrants’ comments section will continue to be filled with dueling doctors and trial lawyers and, barring any new national emergency distracting their attention, the Repubs in the Senate will make a run at instituting a national cap on pain and suffering damages. If they pull the nuclear option of changing the Senate rules in order to get some of Bush’s wackier nut-job nominations through for the Federal bench, then malpractice “reform” might get through too. But even if it passes physicians will quickly figure out that they got it wrong; damages caps don’t help them too much. Instead they should have gone for a real system-changing compromise while they had the chance. But as that would involve giving something up (such as the admission that doctors should be held accountable to national best practices), there’s no way the AMA will allow it.

Consumers, HSAs, CDHPs and all that: The fuss about consultant-directed health plans will continue to grow and their role in the individual insurance market will expand somewhat. I still don’t think that they’ve really got too much chance of being a major force in the employer based-insurance market once VPs of HR start being able to do basic math. However, health plans and banks will slowly get it together on offering integrated products that actually work for consumers. Most important for providers is whether the typical CDHP (or high-deductible plan) comes with a PPO attached as most do now. In that case claims will be routed through the health plans and all the hopes physicians have been holding all these years of the simplicity of direct payment from consumers will be dashed, as the consumer waits for their EOB and gets as confused about it as they do now. Plus they’ll get (or at least see) the discounted rate and won’t want to pay more. I think this is the likely future of HSAs — it’s how mine works– and I foresee physicians being very disappointed by their impact. I also foresee my inbox being filled with missives from ideological libertarians who don’t understand health care and fruitcake insurance salesmen. Oh, and customer service from health plans will continue to suck.

Quality: We may, just, be at the start of some public awareness about quality issues in health care. Obviously Vioxx is part of that, but I also picked up some discussion of quality in more mainstream publications, including in the NY Times Editorial for resolutions for 2005. This is a sleeper issue that may well stay asleep forever, but perhaps something could bring it closer to the forefront, and my hope is that something is a Nobel Prize for Jack Wennberg.

Information Technology: Now we’ve all sung Kum-ba-ya and got the T-shirt, we will return to our caves and notice that David Brailer believes that interoperability (or at least seamless transfer of data) is the reason for making all these vast IT investments. We’ll then also notice that even Brailer says that there are no business reasons for anyone in health care to make their systems inter-operable, and that there won’t be any government regulation forcing them to do so. Then we’ll further notice that Brailer’s office didn’t get funded by Congress and he’ll have to pass the hat around at HHS to buy his staff sandwiches (and pay them); whereas the Brits are putting $20 billion into their IT initiative (and BTW believe it or not are giving Halliburton a job as a watchdog on how the money is spent…yes, that Halliburton!). However, the good news is that some of the bigger private systems, like the Kaisers and the Sutters, will forge ahead with their initiatives but the vast majority of American patients and doctors won’t notice the difference for several more years. The EMR will remain 3-5 years into the future, but it won’t necessarily stay that way forever. (There you go, how about that for a hint of forecasting optimism!)

Specialty Hospitals: A big fight is coming up concerning the end of the moratorium on specialty hospitals. My guess is that the moratorium ends and that hospitals get heavily involved in doing whatever it takes to placate their superstar surgeons, which probably means most of them joint-venturing with them on new facilities. The “haves” versus “have-nots” divide will be exacerbated.

Policy: The Bushies will have a run at promoting the Federalization of AHPs. I suspect that they’ll fail given the strength of the Blues, and the limited capital Bush will have for this. But it’s a new full employment act for insurance fraud if they succeed!

The uninsured: Will continue to be turned back at the Canadian border. If you’re uninsured there’s no hope for significant change this year. But this issue combined with the cost issue will fester away until some Democrat picks it for their 2008 topic and tries to go after Bush’s middle class support with it.

Wildcards: These events probably won’t happen, but if they do it’ll be a big deal

• A major implantable medical device gets recalled, as in needs to be removed from everyone it’s inside of
• Avian flu crosses over and public health systems virtually collapse
• A class action suit against big pharma takes on the anti-tobacco suit properties and dominates the industry.
• The terms of Medicare Drug coverage are so good that almost all seniors join it
• Some Republicans develop a conscience and we get a Congressional opposition to many of the wackier Bush plans.

Blogs: If 2004 was the year of the political blog, 2005 might begin to be the year of mainstreaming of business blogs. My forecast is that bloggers will try to figure out how to make money at this, but that most of them will fail at that (and sadly their numbers will probably include me!)

Soccer: Chelsea will finally win the league after 50 years. OK that’s a fervent hope, but we’re 5 points clear and looking good!

Happy New Year and Welcome to 2005! Every year I put out an email to my friends and family about what I’ve been up to, and what charities and causes I’m supporting. If you’d like to read it, it’s posted on my personal blog here.

THCB Media Packet

Want to reach a weekly audience of thousands of health care industry insiders and watchers? THCB is read by more than a thousand visitors a day, including industry analysts, physicians, investors, Wall Street insiders and executives from every top health system in the country.

Advertise with us and you’ll put your brand in front of a smart & tightly focused demographic, one at the forefront of an evolving marketplace.

From start-ups to new studies

THCB covers the health care spectrum,  providing commentary and insight on industry news, interviews with industry leaders and commentary from some of the top minds in the field. We write about the top new companies in the field, important trends and the issues health care professionals are talking about. Including:

> Hospitals & insurers> Physicians> Health care information technology
> Health policy
> Medical devices
> Electronic medical records
> The pharmaceutical industry
> Regulation and economic issues

Getting Started

Getting started is easy. Just select an ad format and length of run from the list of options below. Then send us a copy of the ad you would like to run together with the web address you would like the spot to link to. In most cases approvals take under 24 hours. Paying is just as easy. We accept Paypal and corporate check. Questions? Email jo**@***************og.com

Advertising Options

Above the
fold

This
prominent placement puts your ad in a can’t miss-spot certain to catch readers
attention: centered in the main sidebar beneath our search feature. Options include box and skyscraper
formats. Your spot will be shown on every page on the site using our main template. (2,000 plus pages.)

Inline

This
approach delivers your message directly in the flow of content between
posts, guaranteeing
maximum exposure. A text box or graphic is placed directly between
spots. We’ll track click through and other data for you.

Text Message
This is a good option for getting word out quickly to the health care industry about a new
product or service. You’ll give us a five line text advert that runs
between posts. (Think of an online format similar to that of the traditional
newspaper classified.) 

Sponsored Links

Good for building exposure for your brand or web site. Places your targeted link in a prominent location in the right sidebar. A limited number of spots are available. Act quickly to reserve yours for 2007. (2 available)

THCB Update

The THCB Update e-mail goes out three to five times a week to an audience of 900 regular readers. Catch the eye of some of the smartest people in the health care industry, including industry observers, Wall Street people and executives at the top health care systems and physician group practices in the country. Email jo**@***************og.com for more info.

Custom Package

We are
happy to work with you to create a specialized content section or other
promotional package emphasizing your brand and targeting a specific sector.

THIS IS A BRIEF COLLECTION of twenty-five posts written for THCB in the nearly two years since I started this project .  You’ll find essays on a wide range of topics in health care policy and health care economics.  You may want to try reading them through end to end (probably ambitious) or you may want to dip in for a quick browse around and then come back later for more.  I’ll update this list with more later when I get a chance. If there is a post you’d particularly like to see here, you can add a comment with your suggestion at the bottom of the page. Cheers! — Matthew

Oh Canada
http://matthewholt.typepad.com/the_health_care_blog/2003/11/policy_oh_canad_1.html

Letter from England
http://matthewholt.typepad.com/the_health_care_blog/2004/01/quality_quickie.htmlIt’s a good year for the Rowe(s)
http://matthewholt.typepad.com/the_health_care_blog/2004/03/health_plans_it.htmlWhy is the individual market such a mess?
 http://matthewholt.typepad.com/the_health_care_blog/2003/12/health_planspol_1.html

Michael Porter sinking into the Healthcare Quaqmire
 http://matthewholt.typepad.com/the_health_care_blog/2004/09/policyhealth_pl_1.html

As you may have guessed CDHP = cost shifting
http://matthewholt.typepad.com/the_health_care_blog/2004/04/health_plans_as.html

For Profits cost more but that’s not the point
 http://matthewholt.typepad.com/the_health_care_blog/2004/06/hospitalspolicy.html

The value of healthcare–interesting issue but appalling analysis
http://matthewholt.typepad.com/the_health_care_blog/2004/01/policyindustry_.html

Why Wall Street hates health care services but doesn’t know it
http://matthewholt.typepad.com/the_health_care_blog/2003/09/why_wall_street.html

PHARMA: The New Yorker, Industry Veteran and Atlas on pharma pricing and
where the industry goes next.
http://matthewholt.typepad.com/the_health_care_blog/2004/10/pharma_the_emne.html

The Real Debate behind Reimportation
http://matthewholt.typepad.com/the_health_care_blog/2004/09/pharma_the_real.html

Drug prices here and there
http://matthewholt.typepad.com/the_health_care_blog/2004/03/pharma_drug_pri.htmlAre Cox-2s over used? http://matthewholt.typepad.com/the_health_care_blog/2003/11/pharmapbms_are_.html

Online detailing and perscribing–taking off at last?
http://matthewholt.typepad.com/the_health_care_blog/2003/08/online_detailin.html

Sorry! Got it all wrong–PBMs save money.
http://matthewholt.typepad.com/the_health_care_blog/2004/07/pbms_sorry_got_.html As I’ve always suspected, Health Care = Communism + Frappuccinos
http://matthewholt.typepad.com/the_health_care_blog/2005/01/policy_as_ive_a.html

Prop 72- Sorry couldn’t help myself
http://matthewholt.typepad.com/the_health_care_blog/2004/11/policypolitics_.html

Why dishonesty rules in our health care "debate"
http://matthewholt.typepad.com/the_health_care_blog/2004/10/policy_why_dish.html

"Producers" comment on how much we should spend on health care.
http://matthewholt.typepad.com/the_health_care_blog/2004/09/policypharma_pr.html International comparisons, or "How does Japan do it?" revisited
http://matthewholt.typepad.com/the_health_care_blog/2004/09/policy_internat.html

Toto, we’re back in Kansas and it’s 1991 again.
http://matthewholt.typepad.com/the_health_care_blog/2004/07/policy_toto_wer.html

Reggie’s back and the intellectual slop goes on
http://matthewholt.typepad.com/the_health_care_blog/2004/04/consumersindust.html

Health Care Costs 101 http://matthewholt.typepad.com/the_health_care_blog/2003/12/policy_health_c.html

User fees, employer-based insurance and why it won’t go away
http://matthewholt.typepad.com/the_health_care_blog/2003/10/policy_user_fee.html

Medicaid–a bleak picture gets bleaker
http://matthewholt.typepad.com/the_health_care_blog/2003/09/medicaida_bleak.html

Jeanne Scott looks at Single payer, MSAs and what employees want: I
editorialize back
http://matthewholt.typepad.com/the_health_care_blog/2003/09/jeanne_scott_lo.html

This post includes links to featured posts worth a close look.

To contact Matthew Holt at THCB please email ma*****@*********lt.netFor more information see my consulting site www.matthewholt.net

The Health Care Blog (THCB) has acquired a
reputation as one of the most respected independent voices in the healthcare
industry. The Wall Street Journal calls us "among the most widely read insider
publications in the field.
Web MD calls us “a free-wheeling discussion of the latest healthcare developments."

Started in August 2003, for most of the first five years of its existence THCB was the mostly exclusive domain of Matthew Holt, who still owns and runs THCB. But a mix of increased consulting work and the growth of the Health 2.0 Conference that
Matthew co-founded with Indu Subaiya in 2007 limited Matthew's time to write every day. And the growth of readership (from a few each day to over 80,000 visits in October 2008) and the interest of other people in writing on THCB has all meant that there's been less of Matthew and much more of
many great authors on the site. And so in March 2008 THCB officially became a group blog, in which all authors (including Matthew) started to use their own byline. (For posts prior to March 2008, no byline means Matthew was the author)

THCB prints original material from many contributors (some regular, some not so regular) and reprints (by permission) great posts from other bloggers. If you are interest in writing something for us, take a look at our writer's guidelines.

John Irvine is the managing editor and handles business development. Requests for information about advertising should go to him.

And Matthew is not sure whether he should be happy or chagrined but since the change to the group blog status, readership has more than doubled!

Contact List

ad sales:    ad******@***************og.compress inquiries:  me*************@***************og.comsubmit a good story: ti**@***************og.com*****@***************og.com“>e-mail matthew: ma*****@***************og.comemail john: jo**@***************og.compress: ***************@***************og.com“>me*************@***************og.comassociate editor: Ian Kibbe – ki*******@***il.com

Musings about the goings-on in American health care from a general health care consultant. Topics can include policy, health insurers, technology and eHealth, physicians, pharma and anything else that grips my fancy. Although my opinions shine through, this blog tries to concentrate on what I think is happening and will happen, rather than what I’d like to happen. Feel free to email me, and to send tips, opinions and requests for work my way.